December 8, 2021 -- Applied Biomath and Celsius Therapeutics are collaborating on the development of a semimechanistic pharmacokinetic/receptor occupancy model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).
Applied Biomath offers software and services to help de-risk and accelerate drug R&D. The company's approach involves working with clients to develop the appropriate mathematical strategy for each unique project, with common biosimulation strategies deployed, including systems pharmacology, mechanistic modeling, pharmacokinetic/pharmacodynamic modeling, bioinformatics, and clinical pharmacology.
Celsius Therapeutics will use the model developed by Applied Biomath to support human dose projections in IBD.
No terms of the agreement were disclosed.